Irwin Mitchell has advised Stockport-based Solo Containment on its sale to ILC Dover.
The acquisition will grow ILC Dover’s global pharmaceutical and biopharmaceutical business, expanding its solutions for high containment and powder transfer to include aseptic flexible isolators, among others.
Solo has supported the life sciences market since 2011, providing customers across Europe, North America, Asia, and Australia, with advanced flexible film containment solutions.
Solo’s flagship products include flexible film containment isolators, targeting niche HPAPI applications for pharmaceutical processing and include many custom-designed platforms.
Solo has pioneered single-use aseptic processing isolators using uni-directional high-volume airflows, and today, all of Solo’s products are based on single-use platforms, a design principle that aligns directly with ILC Dover’s leadership in single-use flexible powder solutions for high containment.
The combined capability set between ILC Dover and Solo will enable pharmaceutical and biopharmaceutical manufacturers to further eliminate costly cleaning processes and achieve maximum productivity and safety without sacrificing reliability.
ILC Dover is a world leader in the design and production of single-use flexible solutions for pharmaceutical and biopharmaceutical manufacturing.
Victoria Zivkovic (Picture), Corporate partner at Irwin Mitchell in Manchester, advised on the deal along with Greg Mazgajczyk.
Law Firms: Irwin Mitchell;
Clients: Solo Containment;